603520 司太立
交易中 03-31 11:01:59
资讯
新帖
简况
3月26日司太立（603520）涨停分析：业绩扭亏、CMO拓展、产能爬坡驱动
证券之星 · 03-26
3月26日司太立（603520）涨停分析：业绩扭亏、CMO拓展、产能爬坡驱动
异动快报：司太立（603520）3月26日9点43分触及涨停板
证券之星 · 03-26
异动快报：司太立（603520）3月26日9点43分触及涨停板
司太立(603520.SH)拟1000万元受让睿石药业20%股权 提升CMO产能
智通财经 · 03-23
司太立(603520.SH)拟1000万元受让睿石药业20%股权 提升CMO产能
每周股票复盘：司太立（603520）控股股东股份质押变动频繁
证券之星 · 02-08
每周股票复盘：司太立（603520）控股股东股份质押变动频繁
司太立（603520）股东胡锦生质押500万股，占总股本1.14%
证券之星 · 02-06
司太立（603520）股东胡锦生质押500万股，占总股本1.14%
司太立（603520）股东胡锦生质押1300万股，占总股本2.97%
证券之星 · 02-03
司太立（603520）股东胡锦生质押1300万股，占总股本2.97%
股市必读：司太立（603520）预计2025年全年归属净利润盈利1000万元至1300万元
证券之星 · 02-02
股市必读：司太立（603520）预计2025年全年归属净利润盈利1000万元至1300万元
每周股票复盘：司太立（603520）预计2025年净利1000万至1300万
证券之星 · 02-01
每周股票复盘：司太立（603520）预计2025年净利1000万至1300万
司太立（603520）披露2025年年度业绩预盈公告，1月30日股价上涨0.86%
证券之星 · 01-30
司太立（603520）披露2025年年度业绩预盈公告，1月30日股价上涨0.86%
司太立(603520.SH)发预盈，预计2025年归母净利润1000万元到1300万元，扭亏为盈
智通财经网 · 01-30
司太立(603520.SH)发预盈，预计2025年归母净利润1000万元到1300万元，扭亏为盈
每周股票复盘：司太立（603520）募投项目结项并补流
证券之星 · 01-18
每周股票复盘：司太立（603520）募投项目结项并补流
司太立（603520）披露子公司完成工商变更登记，1月16日股价下跌0.59%
证券之星 · 01-16
司太立（603520）披露子公司完成工商变更登记，1月16日股价下跌0.59%
司太立（603520）披露募投项目结项及节余资金补流公告，1月13日股价下跌1.16%
证券之星 · 01-13
司太立（603520）披露募投项目结项及节余资金补流公告，1月13日股价下跌1.16%
每周股票复盘：司太立（603520）募投项目结项并补流
证券之星 · 01-02
每周股票复盘：司太立（603520）募投项目结项并补流
司太立（603520）披露拟对募投项目结项并节余资金补流，12月31日股价下跌0.11%
证券之星 · 2025-12-31
司太立（603520）披露拟对募投项目结项并节余资金补流，12月31日股价下跌0.11%
司太立（603520）披露召开2026年第一次临时股东会通知，12月26日股价下跌1.35%
证券之星 · 2025-12-26
司太立（603520）披露召开2026年第一次临时股东会通知，12月26日股价下跌1.35%
司太立最新公告：全资子公司上海司太立获得钆喷酸葡胺注射液药品注册证书
证券之星 · 2025-11-25
司太立最新公告：全资子公司上海司太立获得钆喷酸葡胺注射液药品注册证书
每周股票复盘：司太立（603520）临时股东会通过多项治理议案
证券之星 · 2025-11-23
每周股票复盘：司太立（603520）临时股东会通过多项治理议案
司太立（603520）披露取消监事会及调整董事会人数等议案获通过，11月20日股价下跌2.44%
证券之星 · 2025-11-20
司太立（603520）披露取消监事会及调整董事会人数等议案获通过，11月20日股价下跌2.44%
11月13日司太立涨5.82%，华商品质价值混合A基金重仓该股
证券之星 · 2025-11-13
11月13日司太立涨5.82%，华商品质价值混合A基金重仓该股
加载更多
公司概况
公司名称：
浙江司太立制药股份有限公司
所属行业：
医药制造业
上市日期：
2016-03-09
主营业务：
浙江司太立制药股份有限公司的主营业务是原料药（碘海醇、碘克沙醇、碘帕醇、碘佛醇、盐酸左氧氟沙星、左氧氟沙星、甲磺酸帕珠沙星）、医药中间体、制剂的研发、生产和销售。公司的主要产品是碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、碘美普尔注射液、碘佛醇注射液、钆贝葡胺注射液、造影剂类原料药及中间体、喹诺酮类原料药及中间体、CMO/CDMO类原料药及中间体。
发行价格：
12.15
{"stockData":{"symbol":"603520","market":"SH","secType":"STK","nameCN":"司太立","latestPrice":10.88,"timestamp":1774926119000,"preClose":10.78,"halted":0,"volume":31497430,"delay":0,"changeRate":0.0093,"floatShares":438000000,"shares":438000000,"eps":-0.0668,"marketStatus":"交易中","change":0.1,"latestTime":"03-31 11:01:59","open":10.78,"high":11.28,"low":10.77,"amount":347000000,"amplitude":0.0473,"askPrice":10.88,"askSize":217,"bidPrice":10.87,"bidSize":290,"shortable":0,"etf":0,"ttmEps":-0.0668,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774927800000},"marketStatusCode":2,"adr":0,"adjPreClose":10.78,"symbolType":"stock","openAndCloseTimeList":[[1774920600000,1774927800000],[1774933200000,1774940400000]],"highLimit":11.86,"lowLimit":9.7,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":438409881,"isCdr":false,"pbRate":1.82,"roa":"--","roe":"1.1%","epsLYR":-0.12,"committee":0.403734,"marketValue":4770000000,"turnoverRate":0.0718,"status":0,"floatMarketCap":4770000000},"requestUrl":"/m/hq/s/603520","defaultTab":"news","newsList":[{"id":"2622834618","title":"3月26日司太立（603520）涨停分析：业绩扭亏、CMO拓展、产能爬坡驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2622834618","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622834618?lang=zh_cn&edition=full","pubTime":"2026-03-26 15:37","pubTimestamp":1774510625,"startTime":"0","endTime":"0","summary":"证券之星消息，司太立3月26日涨停收盘，收盘价10.3元。该股于9点43分涨停，1次打开涨停，截止收盘封单资金为2318.53万元，占其流通市值0.51%。今日司太立涨停的可能因素有：2025年业绩扭亏为盈，确立经营拐点；CMO业务加速落地，3月23日公告拟1000万元受让睿石药业20%股权，强化小分子CDMO能力；碘造影剂产能全面爬坡，江西/浙江新产线于2024–2025年陆续达产，叠加碘普罗胺注射液获批及一致性评价通过，产品结构优化与API+制剂一体化进入收获期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600022871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2622881236","title":"异动快报：司太立（603520）3月26日9点43分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622881236?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:45","pubTimestamp":1774489527,"startTime":"0","endTime":"0","summary":"证券之星3月26日盘中消息，9点43分司太立（603520）触及涨停板。其所属行业化学制药目前上涨。领涨股为海森药业。该股为化学原料药，医药概念热股，当日化学原料药概念上涨1.58%，医药概念上涨1.31%。3月25日的资金流向数据方面，主力资金净流出242.95万元，占总成交额1.13%，游资资金净流入465.01万元，占总成交额2.16%，散户资金净流出222.06万元，占总成交额1.03%。近5日资金流向一览见下表：司太立主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600012151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2621778416","title":"司太立(603520.SH)拟1000万元受让睿石药业20%股权 提升CMO产能","url":"https://stock-news.laohu8.com/highlight/detail?id=2621778416","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621778416?lang=zh_cn&edition=full","pubTime":"2026-03-23 15:38","pubTimestamp":1774251536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，司太立(603520.SH)公告，公司拟以1000万元受让李永萍女士持有的江苏睿石药业有限公司(简称“睿石药业”)20.00%的股权。公告显示，睿石药业与国内外知名CDMO企业及一线原研药企建立深度合作。产品线涵盖小分子化合物、氨基酸及其衍生物等多种核心原料，致力于为客户在药物研发早期至申报阶段提供稳定、可靠的高品质材料支持，加速新药开发进程。通过本次交易，有利于公司CMO产能提升及下游客户的开拓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0067412154.USD","BK1515","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1226288253.USD","BK1191","LU2039709279.SGD","LU1226288170.HKD","LU1226287529.USD","LU0315179316.USD","LU1813983027.USD","IE00BZ08YS42.EUR","HK0000165453.HKD","LU1152091168.USD","LU1226287792.SGD","LU1993786604.SGD","IE00BZ08YT58.USD","LU0501845795.SGD","LU1951186391.HKD","LU0140636845.USD","LU0072913022.USD","BK0239","IE0008369823.USD","IE00B543WZ88.USD","BK1521","LU0326950275.SGD","SG9999004220.SGD","IE00B5MMRT66.SGD","01093","603520","LU0880133367.SGD","LU1960683339.HKD","IE0008368742.USD","LU1152091754.HKD","LU0314109678.HKD","LU1008478684.HKD","LU1226287875.USD","LU1807302812.USD"],"gpt_icon":0},{"id":"2609268185","title":"每周股票复盘：司太立（603520）控股股东股份质押变动频繁","url":"https://stock-news.laohu8.com/highlight/detail?id=2609268185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609268185?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:36","pubTimestamp":1770489373,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，司太立报收于10.65元，较上周的10.61元上涨0.38%。本周关注点公司公告汇总：控股股东胡锦生多次解除及新增股份质押，累计质押比例未达50%。解除后剩余被质押股份32,026,800股，占其所持股份71.06%。司太立关于控股股东股份解除质押及新增质押的公告浙江司太立制药股份有限公司控股股东胡锦生于2026年2月4日解除质押11,656,800股，占公司总股本2.66%，占其持股25.86%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2609643765","title":"司太立（603520）股东胡锦生质押500万股，占总股本1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609643765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609643765?lang=zh_cn&edition=full","pubTime":"2026-02-06 18:28","pubTimestamp":1770373681,"startTime":"0","endTime":"0","summary":"证券之星消息，司太立2月6日公开信息显示，股东胡锦生向浙江银通典当有限责任公司合计质押500.0万股，占总股本1.14%。质押详情见下表：截止本公告日，股东胡健已累计质押股份312.32万股，占其持股总数的6.74%，股东胡锦生已累计质押股份3837.0万股，占其持股总数的85.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600033896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2608822482","title":"司太立（603520）股东胡锦生质押1300万股，占总股本2.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608822482","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608822482?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:37","pubTimestamp":1770115045,"startTime":"0","endTime":"0","summary":"证券之星消息，司太立2月3日公开信息显示，股东胡锦生向浙江轻工联典当有限责任公司合计质押1300.0万股，占总股本2.97%。质押详情见下表：截止本公告日，股东胡健已累计质押股份312.32万股，占其持股总数的6.74%，股东胡锦生已累计质押股份4502.68万股，占其持股总数的99.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300033390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2608881849","title":"股市必读：司太立（603520）预计2025年全年归属净利润盈利1000万元至1300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608881849","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608881849?lang=zh_cn&edition=full","pubTime":"2026-02-02 04:10","pubTimestamp":1769976623,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，司太立报收于10.61元，上涨0.86%，换手率1.53%，成交量6.69万手，成交额7061.82万元。业绩披露要点业绩预告司太立发布业绩预告，预计2025年全年归属净利润盈利1000万元至1300万元。公司公告汇总司太立2025年年度业绩预盈公告浙江司太立制药股份有限公司预计2025年年度实现归属于母公司所有者的净利润1,000万元到1,300万元，与上年同期相比实现扭亏为盈；扣除非经常性损益后的净利润预计为250万元到550万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520"],"gpt_icon":0},{"id":"2608077016","title":"每周股票复盘：司太立（603520）预计2025年净利1000万至1300万","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077016?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:33","pubTimestamp":1769887990,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，司太立报收于10.61元，较上周的10.79元下跌1.67%。本周，司太立1月26日盘中最高价报11.17元。司太立发布业绩预告，预计2025年全年归属净利润盈利1000万元至1300万元。公司公告汇总浙江司太立制药股份有限公司预计2025年年度实现归属于母公司所有者的净利润1,000万元到1,300万元，与上年同期相比实现扭亏为盈；扣除非经常性损益后的净利润预计为250万元到550万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2607042318","title":"司太立（603520）披露2025年年度业绩预盈公告，1月30日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607042318","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607042318?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:17","pubTimestamp":1769786232,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，司太立报收于10.61元，较前一交易日上涨0.86%，最新总市值为46.52亿元。该股当日开盘10.51元，最高10.68元，最低10.4元，成交额达7061.82万元，换手率为1.53%。近日，浙江司太立制药股份有限公司发布2025年年度业绩预盈公告。本次业绩预告未经注册会计师审计，具体财务数据以公司正式披露的2025年年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2607101415","title":"司太立(603520.SH)发预盈，预计2025年归母净利润1000万元到1300万元，扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2607101415","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607101415?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:14","pubTimestamp":1769771664,"startTime":"0","endTime":"0","summary":"智通财经APP讯，司太立(603520.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润1000万元到1300万元，与上年同期相比，将实现扭亏为盈。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["603520"],"gpt_icon":0},{"id":"2604190925","title":"每周股票复盘：司太立（603520）募投项目结项并补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2604190925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604190925?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:12","pubTimestamp":1768680729,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，司太立报收于10.14元，较上周的10.02元上涨1.2%。本周，司太立1月13日盘中最高价报10.52元。本周关注点公司公告汇总：司太立审议通过募投项目结项并将节余资金永久补充流动资金。公司公告汇总浙江司太立制药股份有限公司于2026年1月13日召开第一次临时股东会，审议通过关于募集资金投资项目结项、调整投资规模并将节余募集资金永久补充流动资金的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2603023994","title":"司太立（603520）披露子公司完成工商变更登记，1月16日股价下跌0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603023994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603023994?lang=zh_cn&edition=full","pubTime":"2026-01-16 22:50","pubTimestamp":1768575026,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，司太立报收于10.14元，较前一交易日下跌0.59%，最新总市值为44.45亿元。该股当日开盘10.21元，最高10.33元，最低10.05元，成交额达7444.66万元，换手率为1.67%。目前，公司已收到通知，上海司太立已完成工商变更登记手续，注册资本由50,000万元增至56,000万元，并取得上海市金山区市场监督管理局换发的营业执照。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600041598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2603059638","title":"司太立（603520）披露募投项目结项及节余资金补流公告，1月13日股价下跌1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603059638","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603059638?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:48","pubTimestamp":1768315694,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，司太立报收于10.25元，较前一交易日下跌1.16%，最新总市值为44.94亿元。该股当日开盘10.37元，最高10.52元，最低10.24元，成交额达1.47亿元，换手率为3.24%。近日，司太立发布2026年第一次临时股东会决议公告，公司于2026年1月13日召开第一次临时股东会，审议通过关于募集资金投资项目结项、调整投资规模并将节余募集资金永久补充流动资金的议案。出席会议股东及代理人共361人，代表有表决权股份95,228,040股，占公司有表决权股份总数的21.7212%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2600395830","title":"每周股票复盘：司太立（603520）募投项目结项并补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2600395830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600395830?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:56","pubTimestamp":1767297362,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，司太立报收于9.48元，较上周的9.46元上涨0.21%。本周关注点公司公告汇总：司太立拟将募投项目结项，节余资金23.17万元永久补充流动资金。公司公告汇总司太立关于募集资金专户注销的公告浙江司太立制药股份有限公司于2024年5月30日完成2023年向特定对象发行股票，募集资金净额为927,792,434.85元，已按规定设立募集资金专项账户并签署三方监管协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2595677741","title":"司太立（603520）披露拟对募投项目结项并节余资金补流，12月31日股价下跌0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595677741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595677741?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:28","pubTimestamp":1767191299,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，司太立报收于9.4元，较前一交易日下跌0.11%，最新总市值为41.21亿元。该股当日开盘9.4元，最高9.47元，最低9.31元，成交额达5305.28万元，换手率为1.29%。近日，司太立发布关于2023年度向特定对象发行股票募集资金投资项目的进展公告。公告显示，公司拟对募投项目“年产1,550吨非离子型CT造影剂系列原料药项目”进行结项，调整投资规模，并将节余募集资金23.17万元永久补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2594329474","title":"司太立（603520）披露召开2026年第一次临时股东会通知，12月26日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594329474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594329474?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:50","pubTimestamp":1766760627,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，司太立报收于9.48元，较前一交易日下跌1.35%，最新总市值为41.56亿元。近日，司太立发布关于召开2026年第一次临时股东会的通知。公告显示，浙江司太立制药股份有限公司将于2026年1月13日召开2026年第一次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。现场会议将于2026年1月13日15时30分在浙江省仙居县公司行政楼会议室举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2586456447","title":"司太立最新公告：全资子公司上海司太立获得钆喷酸葡胺注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586456447","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586456447?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:41","pubTimestamp":1764056516,"startTime":"0","endTime":"0","summary":"司太立(603520.SH)公告称，公司全资子公司上海司太立近日收到国家药监局核准签发的钆喷酸葡胺注射液《药品注册证书》。该药品主要用于中枢神经（脑及脊髓）、腹、胸、盆腔、四肢等人体脏器和组织的磁共振成像。这是公司继钆贝葡胺注射液之后第二个获得药品注册证书的磁共振造影剂产品，进一步丰富了公司制剂产品管线。药品销售受医药行业政策、招投标、市场环境变化等诸多因素影响而存在不确定性，因此本次获得药品注册证书对公司业绩的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500017551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2585038611","title":"每周股票复盘：司太立（603520）临时股东会通过多项治理议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2585038611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585038611?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:04","pubTimestamp":1763834656,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，司太立报收于9.94元，较上周的11.87元下跌16.26%。本周关注点公司公告汇总：司太立2025年第一次临时股东会审议通过续聘审计机构、取消监事会等多项议案。司太立2025年第一次临时股东会法律意见书北京金诚同达律师事务所就浙江司太立制药股份有限公司2025年第一次临时股东会的召集、召开程序，出席会议人员资格、召集人资格，表决程序及表决结果等事项出具法律意见书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603520","BK0239"],"gpt_icon":0},{"id":"2584303341","title":"司太立（603520）披露取消监事会及调整董事会人数等议案获通过，11月20日股价下跌2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584303341","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584303341?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:15","pubTimestamp":1763648123,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，司太立报收于10.4元，较前一交易日下跌2.44%，最新总市值为45.59亿元。根据近日发布的公告，浙江司太立制药股份有限公司于2025年11月20日召开2025年第一次临时股东会，会议审议通过了续聘2025年度审计机构、对全资子公司增资、取消监事会、调整董事会人数、修订公司章程部分条款以及多项治理制度议案，包括股东会议事规则、董事会议事规则、独立董事制度等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0},{"id":"2583542975","title":"11月13日司太立涨5.82%，华商品质价值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583542975","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583542975?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:26","pubTimestamp":1763022402,"startTime":"0","endTime":"0","summary":"证券之星消息，11月13日司太立涨5.82%，收盘报12.36元，换手率11.42%，成交量50.06万手，成交额6.15亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为华商基金的华商品质价值混合A。华商品质价值混合A目前规模为8.63亿元，最新净值1.7362，较上一交易日下跌0.5%，近一年上涨43.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603520"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774926122788,"stockEarnings":[{"period":"1week","weight":0.1794},{"period":"1month","weight":0.0286},{"period":"3month","weight":0.1456},{"period":"6month","weight":-0.0101},{"period":"1year","weight":0.2447},{"period":"ytd","weight":0.1468}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":-0.0576},{"period":"3month","weight":-0.0105},{"period":"6month","weight":0.0104},{"period":"1year","weight":0.1707},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江司太立制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32629人(较上一季度减少2.66%)","perCapita":"13436股","listingDate":"2016-03-09","address":"浙江省台州市仙居县现代工业集聚区司太立大道1号","registeredCapital":"43840万元","survey":" 浙江司太立制药股份有限公司的主营业务是原料药（碘海醇、碘克沙醇、碘帕醇、碘佛醇、盐酸左氧氟沙星、左氧氟沙星、甲磺酸帕珠沙星）、医药中间体、制剂的研发、生产和销售。公司的主要产品是碘海醇注射液、碘帕醇注射液、碘克沙醇注射液、碘美普尔注射液、碘佛醇注射液、钆贝葡胺注射液、造影剂类原料药及中间体、喹诺酮类原料药及中间体、CMO/CDMO类原料药及中间体。","listedPrice":12.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"司太立(603520)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供司太立(603520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"司太立,603520,司太立股票,司太立股票老虎,司太立股票老虎国际,司太立行情,司太立股票行情,司太立股价,司太立股市,司太立股票价格,司太立股票交易,司太立股票购买,司太立股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"司太立(603520)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供司太立(603520)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}